What's happening in and around the Park? Here's an update from the team at the Illinois Science + Technology Park. |
|
Skokie-based LanzaTech, is a biotech company that works to recycle carbon waste into everyday products and materials like fuels, fabrics and packaging. LanzaTech announced its plans to enter the public market through a merger with special purpose acquisition company AMCI Acquisition Corp. II. The deal will make it the first carbon capture and transformation business in the public space, according to the company.
When the acquisition closes, the combined company is expected to trade under the Nasdaq ticker symbol “LNZA.” The transaction will raise about $275 million in proceeds, money LanzaTech plans to put toward executing its business plan, accelerating commercial operations, funding partner development projects and building out its tech. The deal is set to close in the third quarter of 2022.
“We are showing the world what is possible when we radically rethink how we source, use and dispose of carbon. We are excited to be on this journey,” Holmgren noted.
|
|
“LanzaTech revolutionary technology repurposes waste carbon for use as a feedstock to make the products we use in our daily lives—from yoga pants to jet fuel,” said Dr. Jennifer Holmgren, LanzaTech’s CEO. “Our carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals." |
|
Vetter: Sweeps CMO Leadership Awards |
|
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award was given by the leading trade press publication, Life Science Leader.
Winning all six core categories and three champion ratings validates Vetter as a trusted partner. Vetter’s high-level performance further substantiates its dedicated performance in customer-critical services. Results affirm the approach, vision, and strategy of the company’s daily work for customers.
The CMO Leadership Awards program is unique among other industry awards since winners are chosen according to customer evaluations of the service providers they have actually worked with in the past 18 months. Thus, results cannot be influenced in any manner and are truly representative of actual customer performance.
|
|
“Our result this year is an unprecedented achievement for Vetter and represents a landmark victory for the company,” said Vetter Managing Director Peter Soelkner. “To win in all six categories is exceptional in its own right. However, to be awarded Champion in the areas of Compatibility, Quality and Expertise is particularly rewarding and reflects the day-to-day dedication and hard work of our 5,700 employees on three continents.” |
|
Space Now Available @ISTP |
|
There is laboratory and office space available in 8045 Lamon. Suites, ranging from approximately 10,000 sq. ft. to over 50,000 sq. ft., are ready now. Options appropriately address your access and security concerns. Interested? Click here!
8045 Lamon (Research to Commercialization)
- 4 story, 163,000 square feet
- Gold LEED rated “green” facility
- Conference Center and Auditorium
- Areas for meetings, collaboration and socialization
Design your customized lab & office facilities at 8030 Lamon. (Flexible Options for Development)
- Flexible build to suit options
- Up to 200,000 square feet of office and development space
|
|
“The Illinois Science + Technology Park is a significant contributor to Skokie’s employment base and economic growth,” said Skokie Mayor George Van Dusen. “The park continues to grow and contribute to Skokie’s economy while also providing economic stimulus for the state and Midwest region.” |
|
Highpoint at 8000 North Ribbon Cutting |
|
Community leaders from the Village and Skokie Chamber of Commerce gathered with the development and leasing teams for an official ribbon-cutting ceremony at the new Highpoint at 8000 North luxury rental building on the northwest corner of Lincoln Avenue and Oakton Street in Downtown Skokie. Leasing is well underway and new residents are already moving in.
|
|
Charles River Bioanalysis (Nonclinical & Clinical |
|
Comprehensive preclinical bioanalysis is key at every stage of product development. At Charles River, bioanalytical services are intertwined with discovery, preclinical, and clinical capabilities. From method development through clinical sample analysis, Charles River is dedicated to performing accurate, reliable, and streamlined bioanalytical services for the most challenging programs to help you make confident research decisions.
Global bioanalytical laboratories use a wide range of techniques and technology platforms to meet the needs of customers. With 15 facilities worldwide expertise spans:
- Chromatography
- Mass spectrometry
- Immunochemistry
- Cell-based assays
- Flow cytometry
- Molecular biology
Also supported are PK/TK, pharmacology, bioequivalence, and bioavailability studies, as well as biomarker assays from early discovery and preclinical bioanalysis to clinical and post marketing studies. Bioanalysis is somewhat unique in that it is required for the evaluation of a therapeutic throughout the entire drug development cycle. To learn more, click here.
|
|
From start to finish, scientists are universally connected and can support your complex challenges through a bioanalytical network of experts, offer rapid lead-in times, and help you select the most reliable analytical methodology with quality standard operating procedures (SOPs) in order to meet critical deadlines. When you choose Charles River as your partner for bioanalysis, you’ll receive full support as your focus changes from the early discovery scientific stages of lead selection/optimization and nonclinical development (where developing and refining methods in a variety of species and biological matrices is critical) to the later clinical stage challenges of sample collection, logistics and handling along with the significant data management needs. |
|
What's Coming in 2022? Insights from NU |
|
After a year filled with unprecedented challenge and uncertainty, can the lessons of 2021 prepare us for a more stable year ahead? Northwestern Now asked experts across campus to share their predictions for 2022 on a variety of topics from COVID-19 and the supply chain to artificial intelligence and local news. For more predictions, click here.
|
|
“I expect an explosion of activity in artificial intelligence (AI) for areas beyond what we typically associate it with, including newsworthy advances in synthetic biology and the creation of new medicines,” said Chad Mirkin, director of the International Institute for Nanotechnology.
“But the most significant advances may come through deploying AI to address the materials genome. To meet our ambitions for clean energy and zero emissions, we need materials for fuel cells and catalysts with unprecedented power and capabilities- materials that don’t exist today. And AI, when trained on the appropriate data sets, can direct us to structures with the properties we need".
|
|
Cour Pharma Expands at ISTP |
|
To meet the increasing demand for medical research space in the Chicagoland area, Cour Pharmaceuticals' life science and emerging biotechnology footprint is expanding within the Illinois Science and Technology Park in Skokie, Ill. With the addition, Cour Pharmaceuticals now leases around 25,000 sq. ft. in the park.
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
|
|
"Continued rapid growth for high-potential life science startups are emerging in Chicago and in addition to talent, life sciences companies like COUR will continue to need access to more specialized wet and dry lab space along with capital," said COUR Pharmaceuticals CEO John Puisis.
|
|
NuMat Named Chemical Industry Disrupter |
|
The chemicals and materials industry is going to see massive disruption in the next 20 years, and experts at Lux Research have identified startups and technologies leading the evolution of the industry.
The Chemicals & Materials Company of 2040 – The chemicals and materials industry is being transformed by pressure on energy and feedstocks as well as new digital business models. These changes will drive tighter integration among products, materials, and processes, and new platforms like NuMat’s metal-organic frameworks (MOFs) or Metamaterial’s functional metamaterials are key tools
|
|
|
ISTP Hosts Scientists Solutions |
|
The team at ISTP hosted scientists solutions, a range of science suppliers in the atrium of the 8045 Lamon Building
A number of representatives from various science supply companies reached out and shared information with the business teams and scientists who work at the park.
|
|
|
Lighting Up Life Sciences in Illinois |
|
Illinois Biotechnology Innovation Organization (iBIO) announced the appointment of Marilyn Vetter as its new chair. Vetter is group vice president, US access strategy at Horizon Therapeutics. During 30 years in the pharma industry, she has held leadership roles in government affairs, managed markets and sales. Prior to joining Horizon, she spent 15 years at Takeda, where she led the company’s government and public affairs efforts for Illinois and nine other states in the Midwest. Before that, she spent seven years at Organon Inc. in positions of increasing responsibility in managed markets and sales.
Vetter in an interview noted "Chicagoland has had the most significant increase in bioscience venture capital funding of any major U.S. market over the past three years, with nearly one million square feet of Class A lab space either delivered or under construction" For the entire interview, click here. |
|
|
|
|
|
Learn About the LanzaTech Story |
|
|
|
|
|
|
